Company announcements and programme status are published on this page. For media or scientific enquiries, write to info@finnegens.com.
Our five programmes — Fin2678, Fin0311, Fin529, Fin608 and Fin611 — are at candidate-selection and preclinical stage. IND-enabling work is in preparation for the lead metabolic assets.
Work continues across four platforms: half-life extension, regeneration-oriented peptide engineering, multi-target agonist engineering and fusion-protein engineering.
We welcome scientific exchange and collaboration; see Partnering for the models we support.
Statements about our programmes originate from this website. We do not rely on third-party summaries of our work.